Sana Biotechnology Target of Unusually Large Options Trading (NASDAQ:SANA)

Sana Biotechnology, Inc. (NASDAQ:SANA) was the recipient of unusually large options trading activity on Monday. Stock traders acquired 2,613 put options on the company. This is an increase of approximately 148% compared to the typical volume of 1,055 put options.

Wall Street Analyst Weigh In

Several research firms recently weighed in on SANA. Rodman & Renshaw began coverage on Sana Biotechnology in a research report on Wednesday, June 26th. They set a “buy” rating and a $16.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Sana Biotechnology in a research report on Thursday, May 9th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $12.75.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Victory Capital Management Inc. bought a new stake in Sana Biotechnology in the 4th quarter valued at $54,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Sana Biotechnology by 42.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,257 shares of the company’s stock valued at $66,000 after acquiring an additional 4,815 shares during the period. Simplex Trading LLC raised its position in Sana Biotechnology by 31.3% in the fourth quarter. Simplex Trading LLC now owns 18,080 shares of the company’s stock worth $73,000 after purchasing an additional 4,313 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Sana Biotechnology by 351.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,800 shares of the company’s stock worth $93,000 after purchasing an additional 17,753 shares during the period. Finally, E Fund Management Co. Ltd. boosted its holdings in Sana Biotechnology by 40.0% during the fourth quarter. E Fund Management Co. Ltd. now owns 23,361 shares of the company’s stock valued at $95,000 after purchasing an additional 6,673 shares in the last quarter. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Sana Biotechnology Stock Performance

Shares of SANA opened at $6.29 on Wednesday. The company has a 50-day simple moving average of $6.60 and a 200-day simple moving average of $7.58. Sana Biotechnology has a 52 week low of $2.74 and a 52 week high of $12.00. The firm has a market capitalization of $1.39 billion, a P/E ratio of -4.11 and a beta of 1.46.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02). As a group, equities analysts forecast that Sana Biotechnology will post -1.15 earnings per share for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.